Esperion to Report Second Quarter 2019 Financial Results August 8, 2019
July 30, 2019 16:15 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 30, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report second quarter 2019 financial results on August 8, 2019 before the U.S. financial markets...
Esperion and Oberland Capital Announce $200 Million Funding Agreement
June 26, 2019 16:10 ET
|
Esperion Therapeutics, Inc.
- $125 Million Upfront, $25 Million Upon FDA Approval, and $50 Million at Esperion’s Option After Launch -- Initial Mid-Single Digit Repayment Rate on U.S. Revenue to Step Down to Less than One...
Esperion Announces the Appointment of Tracy M. Woody to Board of Directors
May 30, 2019 16:15 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 30, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Tracy M. Woody as a Class I director, with a term expiring at the 2020 meeting of...
Esperion to Participate in Upcoming Investor Conferences
May 28, 2019 07:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 28, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will participate in analyst-led fireside chats with investors at the following conferences:...
Esperion to Participate in Upcoming Investor Conferences
May 10, 2019 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 10, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will participate in analyst-led fireside chats with investors at the following conferences:...
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter Financial Results
May 08, 2019 07:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 08, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the first quarter ended March...
Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review
May 05, 2019 17:00 ET
|
Esperion Therapeutics, Inc.
– Bempedoic Acid is an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor that Reduces Cholesterol and Fatty Acid Synthesis in the Liver –– February 21, 2020 PDUFA Target Date Goal for Bempedoic Acid...
Update in Lawsuit for Investors in NASDAQ: ESPR shares against Esperion Therapeutics, Inc. announced by Shareholders Foundation
January 29, 2019 08:45 ET
|
Shareholders Foundation, Inc.
SAN DIEGO, Jan. 29, 2019 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR). ...
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Esperion Therapeutics, Inc.
May 10, 2018 12:08 ET
|
Federman & Sherwood
OKLAHOMA CITY, May 10, 2018 (GLOBE NEWSWIRE) -- Federman & Sherwood announces that on May 7, 2018, a class action lawsuit was filed in the United States District Court for the District of...
Esperion Announces the Appointment of Jeffrey Berkowitz to Board of Directors
December 14, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...